Site-Specific Identification and Quantitation of Endogenous SUMO Modifications Under Native Conditions

Total Page:16

File Type:pdf, Size:1020Kb

Site-Specific Identification and Quantitation of Endogenous SUMO Modifications Under Native Conditions ARTICLE DOI: 10.1038/s41467-017-01271-3 OPEN Site-specific identification and quantitation of endogenous SUMO modifications under native conditions Ryan J. Lumpkin1, Hongbo Gu2, Yiying Zhu2, Marilyn Leonard3, Alla S. Ahmad 1, Karl R. Clauser4, Jesse G. Meyer 1, Eric J. Bennett 3 & Elizabeth A. Komives1 fi fi 1234567890 Small ubiquitin-like modi er (SUMO) modi cation regulates numerous cellular processes. Unlike ubiquitin, detection of endogenous SUMOylated proteins is limited by the lack of naturally occurring protease sites in the C-terminal tail of SUMO proteins. Proteome-wide detection of SUMOylation sites on target proteins typically requires ectopic expression of mutant SUMOs with introduced tryptic sites. Here, we report a method for proteome-wide, site-level detection of endogenous SUMOylation that uses α-lytic protease, WaLP. WaLP digestion of SUMOylated proteins generates peptides containing SUMO-remnant diglycyl- lysine (KGG) at the site of SUMO modification. Using previously developed immuno-affinity isolation of KGG-containing peptides followed by mass spectrometry, we identified 1209 unique endogenous SUMO modification sites. We also demonstrate the impact of protea- some inhibition on ubiquitin and SUMO-modified proteomes using parallel quantitation of ubiquitylated and SUMOylated peptides. This methodological advancement enables deter- mination of endogenous SUMOylated proteins under completely native conditions. 1 Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093-0378, USA. 2 Proteomic Service Group Cell Signaling Technology, 3 Trask Lane, Danvers, MA 01923, USA. 3 Cell and Developmental Biology, University of California, San Diego, La Jolla, CA 92093-0380, USA. 4 Broad Institute of MIT and Harvard, 415 Main St, Cambridge, MA 02142, USA. Eric J. Bennett and Elizabeth A. Komives contributed equally to this work. Correspondence and requests for materials should be addressed to E.J.B. (email: [email protected]) or to E.A.K. (email: [email protected]) NATURE COMMUNICATIONS | 8: 1171 | DOI: 10.1038/s41467-017-01271-3 | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01271-3 fi he family of small ubiquitin-like modi er (SUMO) pro- a sp|P0CG48|UBC_HUMAN QKESTLHLVLRLRGG Tteins in humans includes four distinct genes with three sp|P63165|SUMO1_HUMAN EEEDVIEVYQEQTGG types of members: SUMO1, SUMO2/3 (which differ by sp|P61956|SUMO2_HUMAN EDEDTIDVFQQQTGG only three residues), and SUMO4. SUMO proteins regulate the sp|P55854|SUMO3_HUMAN EDEDTIDVFQQQTGG function of various proteins by reversible covalent isopeptide sp|Q6EEV6|SUMO4_HUMAN EDEDTIDVFQQPTGG bond attachment between the C terminus of SUMO and a free ε- amine group typically on lysine residues within target proteins1, bc similar to ubiquitin (Ub). Ub conjugation mainly targets proteins Ub RGG K Target Sm TGG K Target for degradation by the proteasome, but has also been implicated 2 in DNA repair, receptor signaling, and cell communication . The Trypsin WaLP function of SUMO conjugation on target proteins is similarly cleavage cleavage diverse with SUMOylation catalyzing alteration of protein activity for targets involved in gene expression, DNA repair, 1,3 nuclear import, heat shock, cell motility, and lipid metabolism . GG -K GG -K SUMO targets are generally low-abundance proteins, and the amount of the modification at steady state is also low4. Given its importance in numerous cellular functions, several groups have developed proteomic methods for analysis of SUMOylated Diglycyl-lysine IP Diglycyl-lysine IP proteins. Three general approaches have been previously utilized to GG -K GG -K isolate and identify the SUMOylated proteome5. Ectopic expres- sion of epitope-tagged SUMO followed by standard isolation Nanoscale Nanoscale techniques and mass spectrometry has been widely used in a LC-MS/MS LC-MS/MS – variety of organisms6 10. These approaches have yielded various maps of SUMO-interacting proteins but few sites of SUMOyla- MS1 MS1 tion are identified by this approach and the extent to which fi exogenous expression of modi ed SUMOs alters substrate tar- MS2 MS2 Intensity geting is unknown. Immuno-affinity approaches utilizing anti- Intensity bodies that recognize endogenous SUMO2/3 or SUMO1 have been used to identify SUMO-interacting proteins under endo- m/z m/z 4 genous conditions . However, as with the epitope-tagging fi fi Fig. 1 A strategy for mapping endogenous SUMO-modi cation sites. approach, few actual sites of SUMO modi cation were identi- a C-terminal sequence alignment of processed human SUMO1-4 and fied using this method. Therefore, methods that allow proteome- fi ubiquitin. The proximal amino acid to the diGlycine C-terminal residues is level identi cation of endogenous SUMOylation sites are needed. indicated in red. b Schematic depicting the Ub site mapping strategy. A robust proteomic method has been developed to measure fi 11 Proteins modi ed by ubiquitin are digested with trypsin leaving a diGlycine thousands of endogenous ubiquitylation sites . The method attached to the ε-amine of the lysine where ubiquitin was attached. An takes advantage of the C-terminal sequence of Ub (RGG) antibody specific for KGG-peptides is used to enrich peptides from (Fig. 1a). When cleaved with trypsin, ubiquitylated substrate ubiquitylated sites that are then identified by mass spectrometry. c The proteins will generate peptides containing a Ub-remnant diglycyl- same as b but WaLP digestion is used to generate the KGG-peptides from lysine (KGG) that can be enriched using specific antibodies and – SUMO attachment sites identified by tandem mass spectrometry (Fig. 1b)12 14. Instead of the trypsin-friendly arginine residue preceding the C-terminal diGlycine sequence observed in the processed Ub sequence, fi mature human SUMO paralogs have a threonine preceding the preclude analysis of SUMO-modi cation sites in native settings C-terminal diGlycine sequence and no other tryptic cleavage sites or from human tissues. Currently, no method exists for identi- near the C terminus (Fig. 1a). To overcome this problem, various fying endogenous SUMO sites on a global proteome scale without introduction of mutant SUMO. schemes that introduce mutations within the C terminus of α SUMO to render it more amenable to trypsin-based cleavage and We recently described the application of wild-type -lytic fi protease (WaLP) to proteome digestion for shotgun pro- identi cation by mass spectrometry have been developed for 21 fi global profiling of SUMO attachment sites15,16. Several groups teomics . Although relatively relaxed speci city was observed, fi WaLP prefers to cleave after threonine residues and rarely cleaved have reported global pro ling approaches in which mutant 21 SUMOs with various affinity tags and protease recognition sites after arginine . In addition, WaLP generates peptides of the same average length as trypsin despite its more relaxed substrate were introduced into cells. For example, Hendriks et al. intro- fi 21 duced a lysine-deficient SUMO-3 with a C-terminal trypsin speci city . We show here that WaLP cleaves at the C-terminal – 17,18 TGG sequence (all SUMO paralogs) leaving a SUMO-remnant cleavage site, His10 SUMO-3 K0 Q87R . The SUMOylated proteins were enriched by immobilized metal affinity chromato- KGG at the position of SUMO attachment in target proteins. fi The resulting KGG-containing peptides can then be identified graphy (IMAC) and digested with Lys-C. Peptides modi ed with fi fi SUMO were then purified again with IMAC and finally digested using methods already developed for pro ling the Ub-modi ed with trypsin to generate a five amino acid C-terminal SUMO- proteome as described above (Fig. 1c). The method allows iden- fi tification of SUMO attachment sites under completely native remnant modi cation. This group has compiled all available data fi fl resulting in 7327 SUMOylation sites in 3617 proteins17. Other conditions using the Ub-pro ling work ow by simply substitut- ing WaLP for trypsin. The same sample can be subjected to groups have used similar engineering approaches to express fi mutant SUMOs and identify up to 1000 unique SUMOylation analysis of both the Ub- and SUMO-modi ed proteomes simply 15,16,18–20 by digesting the sample with either trypsin or WaLP, respectively. sites upon induction of cell stress . While these methods fi have proved effective in mapping SUMOylation sites, they all We demonstrate the effectiveness of this parallel identi cation of require exogenous expression of mutant version of SUMO, which ubiquitylation and SUMOylation sites in cells treated with 2 NATURE COMMUNICATIONS | 8: 1171 | DOI: 10.1038/s41467-017-01271-3 | www.nature.com/naturecommunications NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01271-3 ARTICLE proteasome inhibitors. We provide the description a unique sample. This method can be simply applied to any sample, method of identifying proteins containing individual lysine resi- including human tissues samples, to identify endogenous dues that are modified by both SUMO and Ub from the same SUMOylation sites. a Hendricks et al. (7710) This study (1209) 370 826 6661 679 Phosphosite Plus (780) b Precursor m/z 632.3327, z=2 50 b2 b3 b4 b5 b7 b8 b9 b9[+2] y9 y7 y6 y5 y4 y3 y2 y7 y6 25 b8 y4 b9-H2O b3 b7 b4 y5 y9 b5-H O y3 2 y2-H2O y2 b9 b2 m/z 200 300 400 500 600 700 800 900 1000 1100 1200 m/z c Precursor m/z 703.8680, z=2 100 b3 b4 b5 b6 b7 b8 b9 b6 y10 y9y8 y7 y6 y5 y3 y5 b7-NH y9 b3 3 50 y6 y7 b5 y9-H O y8 2 y9-NH 3 b9 b8 y10-NH3 y3-H O b3 b4 2 b7 -H2O y3-NH3 m/z 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 m/z Fig. 2 Summary of SUMOylation site identifications from this study and comparison with previous studies. a Venn diagram showing overlap between the 1209 SUMO sites identified in this study from both Hela and HCT116 cell lines (blue) and all SUMO modifications from either Hendriks et al.
Recommended publications
  • Progress in the Discovery of Small Molecule Modulators of Desumoylation
    Curr. Issues Mol. Biol. (2020) 35: 17-34. Progress in the Discovery of Small Molecule Modulators of DeSUMOylation Shiyao Chen, Duoling Dong, Weixiang Xin and Huchen Zhou* School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China. *Correspondence: [email protected] htps://doi.org/10.21775/cimb.035.017 Abstract protein–protein interactions, gene transcription, SUMOylation and DeSUMOylation are reversible genome integrity, and DNA replication and repair protein post-translational modifcation (PTM) (Wilkinson and Henley, 2010; Vierstra, 2012; processes involving small ubiquitin-like modifer Bailey et al., 2016). In 1995, Meluh and Koshland (SUMO) proteins. Tese processes have indis- (1995) identifed Smt3 in Saccharomyces cerevi- pensable roles in various cellular processes, such siae, which is the earliest report within this fled. as subcellular localization, gene transcription, and Two years later, based on the sequence similarity DNA replication and repair. Over the past decade, between ubiquitin and a new 11.5-kDa protein, increasing atention has been given to SUMO- ubiquitin/SMT3, the name SUMO was formally related pathways as potential therapeutic targets. proposed for the frst time (Mahajan et al., 1997). Te Sentrin/SUMO-specifc protease (SENP), Although SUMO modifcation is closely which is responsible for deSUMOylation, has related to the progression of various diseases, such been proposed as a potential therapeutic target as cancers and cardiac disorders, it has aroused in the treatment of cancers and cardiac disorders. increasing atention as a potential therapeutic target Unfortunately, no SENP inhibitor has yet reached in recent years, especially concerning the Sentrin/ clinical trials. In this review, we focus on advances SUMO-specifc protease (SENP), which is the key in the development of SENP inhibitors in the past regulator of deSUMOylation.
    [Show full text]
  • Genetic Polymorphism of SUMO-Specific Cysteine Proteases − SENP1 and SENP2 in Breast Cancer
    Pathol. Oncol. Res. DOI 10.1007/s12253-016-0064-7 ORIGINAL ARTICLE Genetic Polymorphism of SUMO-Specific Cysteine Proteases − SENP1 and SENP2 in Breast Cancer Alicja Mirecka1 & Zbigniew Morawiec2 & Katarzyna Wozniak1 Received: 14 December 2015 /Accepted: 26 April 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract SENP proteases take part in post-translational mod- risk of metastases in women with the genotype C/C (OR ification of proteins known as sumoylation. They catalyze =2.07, 95 % CI 1.06–4.05) and allele C (OR =2.10 95 % CI three distinct processes during sumoylation: processing of 1.10–4.01) of the c.1691 + 36C > T SENP1 gene polymor- SUMO protein, deconjugation of SUMO from the target pro- phism. Moreover, we observed reduced risk in women with tein, and chain editing which mentions to the dismantling of the allele T (OR =0.48, 95 % CI 0.25–0.91) in this polymor- SUMO chain. Many proteins that are involved in the basic phic site. In the case of SENP2 gene polymorphism we ob- processes of cells, such as regulation of transcription, DNA served that the A/A genotype correlated with the lack of es- repair or cell cycle control, are sumoylated. The aim of these trogen receptor (OR =1.94, 95 % CI 1.04–3.62). Our results studies was to investigate an association between polymorphic suggest that the variability of the SENP1 and SENP2 genes variants (SNPs) of the SENP1 gene (c.1691 + 36C > T, may play a role in breast cancer occurrence.
    [Show full text]
  • The Epstein-Barr Virus Oncoprotein, LMP1, Regulates the Function of SENP2, a SUMO-Protease Received: 3 April 2018 Thomas L
    www.nature.com/scientificreports OPEN The Epstein-Barr Virus Oncoprotein, LMP1, Regulates the Function of SENP2, a SUMO-protease Received: 3 April 2018 Thomas L. Selby, Natalie Biel, Matthew Varn, Sheetal Patel , Akash Patel, Leslie Hilding, Accepted: 12 June 2019 Ashley Ray, Tabithia Ross, Wyatt T. Cramblet, C. Randall Moss, Angela J. Lowrey & Published: xx xx xxxx Gretchen L. Bentz Epstein-Barr virus (EBV) latent membrane protein-1 (LMP1) activates numerous signal transduction pathways using its C-terminal activating regions. We reported that LMP1 increased global levels of sumoylated proteins, which aided the oncogenic nature of LMP1. Because increased protein sumoylation is detected in numerous cancers, we wanted to elucidate additional mechanisms by which LMP1 modulates the sumoylation machinery. Results indicated that SUMO-protease activity decreased in a LMP1-dependent manner, so we hypothesized that LMP1 inhibits SUMO-protease activity, resulting in reduced de-sumoylation of cellular proteins, which contributes to the detected accumulation of sumoylated proteins in EBV-positive lymphomas. Focusing on SENP2, fndings revealed that LMP1 expression corresponded with increased sumoylation of SENP2 at K48 and K447 in a CTAR-dependent manner. Interestingly, independent of LMP1-induced sumoylation of SENP2, LMP1 also decreased SENP2 activity, decreased SENP2 turnover, and altered the localization of SENP2, which led us to investigate if LMP1 regulated the biology of SENP2 by a diferent post-translational modifcation, specifcally ubiquitination. Data showed that expression of LMP1 inhibited the ubiquitination of SENP2, and inhibition of ubiquitination was sufcient to mimic LMP1-induced changes in SENP2 activity and trafcking. Together, these fndings suggest that LMP1 modulates diferent post- translational modifcations of SENP2 in order to modulate its biology and identify a third member of the sumoylation machinery that is manipulated by LMP1 during latent EBV infections, which can afect oncogenesis.
    [Show full text]
  • Epstein-Barr Virus Viral Protein Lmp1 Increases Rap1
    EPSTEIN-BARR VIRUS VIRAL PROTEIN LMP1 INCREASES RAP1 SUMOYLATION, ENHANCING TELOMERE MAINTENANCE DURING TUMORIGENESIS By WYATT TYLER CRAMBLET B.S., Biology, Gordon State College, 2016 A Thesis Submitted to the Faculty of Mercer University School of Medicine in Partial Fulfillment of the Requirements for the Degree MASTER OF SCIENCE IN BIOMEDICAL SCIENCE Macon, GA 2018 EPSTEIN-BARR VIRUS VIRAL PROTEIN LMP1 INCREASES RAP1 SUMOYLATION, ENHANCING TELOMERE MAINTENANCE DURING TUMORIGENESIS By WYATT TYLER CRAMBLET Approved: ___________________________________________ Date _________ Gretchen L. Bentz, Ph.D. Faculty Advisor for Thesis ___________________________________________ Date _________ Richard O. McCann, Ph.D. Thesis Committee Member ___________________________________________ Date _________ Laura Silo-Suh, Ph.D. Thesis Committee Member ___________________________________________ Date _________ Jon Shuman, Ph.D. Thesis Committee Member ___________________________________________ Date _________ Jean Sumner, MD Dean, Mercer University School of Medicine ACKNOWLEDGEMENTS I would like to thank the National Institutes of Health for providing the funding for this project and Mercer University School of Medicine for the opportunity for discovery and knowledge this experience has provided me. My utmost respect and gratitude goes to Dr. Gretchen Bentz. Along the course of my research Dr. Bentz has always provided what I required to be successful: materials, focus, experience, and understanding. Her guidance at both the lab and the writing desk is what has allowed me to accomplish the greatest achievement of my academic career. I thank Dr. Richard McCann and Dr. Christy Bridges who have been the Directors of the Master of Science Biomedical Sciences Program. Their leadership has been invaluable to my peers and me for becoming the professionals we set out to be.
    [Show full text]
  • UNIVERSITY of CALIFORNIA RIVERSIDE Development of Quantitative FRET Technology for SENP Enzyme Kinetics Determinations and High
    UNIVERSITY OF CALIFORNIA RIVERSIDE Development of Quantitative FRET Technology for SENP Enzyme Kinetics Determinations and High-sensitive High-throughput Screening Assay for Protease Inhibitor Discovery A Dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Bioengineering by Yan Liu December 2012 Dissertation Committee: Dr. Jiayu Liao, Chairperson Dr. Jerome Schultz Dr. David Kisailus Dr. Dimitrios Morikis Copyright by Yan Liu 2012 ii The Dissertation of Yan Liu is approved: Committee Chairperson University of California, Riverside iii Acknowledgements I would like to thank Dr. Jiayu Liao for his great support in my Ph.D training, and Dr. Jerome Schultz, Dr. David Kisailus, Dr. Dimitrios Morikis for their helpful advice. Dr. Morikis and Dr. Chris Kieslich offered the computational method to determine the SUMO4 mutation sites. Dr. Victor Rodgers and Dr. Jerome Schultz provided valuable advice for calculation model optimization. Dr. David Carter helped a lot on compound screening instrumentation. I also have to thank all of the members in Dr. Liao’s group for very close collaborative work and helpful discussion, especially Dr. Yang Song and Dr. Yongfeng Zhao’s help for teaching and training and Ms. Ling Jiang’s technical help, Ms. Hong Xu’s help for instrument maintenance. This work is supported by funding from University of California-Riverside and the National Institutes of Health. The text of this dissertation, in part, is a reprint of the material as is appeared in Front. Biol. 2012, Vol 7 (1), p57-64; Anal. Biochem . 2012, 422, p14-21. Listed in the publication, Dr. Jiayu Liao supervised the research which forms the basis for this dissertation, Yang Song provided theoretical help for spectrum analysis, Vipul Madahar provided technical help during the research.
    [Show full text]
  • Site-Specific Characterization of Endogenous Sumoylation Across
    ARTICLE DOI: 10.1038/s41467-018-04957-4 OPEN Site-specific characterization of endogenous SUMOylation across species and organs Ivo A. Hendriks 1, David Lyon 2, Dan Su3, Niels H. Skotte1, Jeremy A. Daniel3, Lars J. Jensen2 & Michael L. Nielsen 1 Small ubiquitin-like modifiers (SUMOs) are post-translational modifications that play crucial roles in most cellular processes. While methods exist to study exogenous SUMOylation, 1234567890():,; large-scale characterization of endogenous SUMO2/3 has remained technically daunting. Here, we describe a proteomics approach facilitating system-wide and in vivo identification of lysines modified by endogenous and native SUMO2. Using a peptide-level immunoprecipi- tation enrichment strategy, we identify 14,869 endogenous SUMO2/3 sites in human cells during heat stress and proteasomal inhibition, and quantitatively map 1963 SUMO sites across eight mouse tissues. Characterization of the SUMO equilibrium highlights striking differences in SUMO metabolism between cultured cancer cells and normal tissues. Tar- geting preferences of SUMO2/3 vary across different organ types, coinciding with markedly differential SUMOylation states of all enzymes involved in the SUMO conjugation cascade. Collectively, our systemic investigation details the SUMOylation architecture across species and organs and provides a resource of endogenous SUMOylation sites on factors important in organ-specific functions. 1 Proteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark. 2 Disease Systems Biology Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark. 3 Protein Signaling Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark.
    [Show full text]
  • Emerging Applications of Metabolomic and Genomic Profiling in Diabetic Clinical Medicine
    Reviews/Commentaries/ADA Statements REVIEW Emerging Applications of Metabolomic and Genomic Profiling in Diabetic Clinical Medicine AINE M. MCKILLOP, PHD however, powerful methodologies are now PETER R. FLATT, PHD available for exploitation of novel quantita- tive and qualitative disease-related biomark- ers. Novel biomarkers are needed that are Clinical and epidemiological metabolomics provides a unique opportunity to look at genotype- independent of known clinical risk factors. phenotype relationships as well as the body’s responses to environmental and lifestyle factors. fl Fundamentally, metabolomics aims to Fundamentally, it provides information on the universal outcome of in uencing factors on monitor changes in products of metabo- disease states and has great potential in the early diagnosis, therapy monitoring, and understand- lism and provide valuable information on ing of the pathogenesis of disease. Diseases, such as diabetes, with a complex set of interactions fl between genetic and environmental factors, produce changes in the body’s biochemical profile, arangeofin uencing factors and gene- thereby providing potential markers for diagnosis and initiation of therapies. There is clearly related outcomes. Exploitation of genomic a need to discover new ways to aid diagnosis and assessment of glycemic status to help reduce technology in recent times has resulted in diabetes complications and improve the quality of life. Many factors, including peptides, proteins, many technical advances, and genomic metabolites, nucleic acids, and polymorphisms, have been proposed as putative biomarkers for analysis has now emerged as a valuable diabetes. Metabolomics is an approach used to identify and assess metabolic characteristics, changes, tool in predicting the body’s response to and phenotypes in response to influencing factors, such as environment, diet, lifestyle, and path- fi stimuli caused by disease or injury.
    [Show full text]
  • Pathway Entry Into the T Lymphocyte Developmental Molecular Dissection of Prethymic Progenitor
    The Journal of Immunology Molecular Dissection of Prethymic Progenitor Entry into the T Lymphocyte Developmental Pathway1 C. Chace Tydell,2 Elizabeth-Sharon David-Fung,2,3 Jonathan E. Moore, Lee Rowen,4 Tom Taghon,5 and Ellen V. Rothenberg6 Notch signaling activates T lineage differentiation from hemopoietic progenitors, but relatively few regulators that initiate this program have been identified, e.g., GATA3 and T cell factor-1 (TCF-1) (gene name Tcf7). To identify additional regulators of T cell specification, a cDNA library from mouse Pro-T cells was screened for genes that are specifically up-regulated in intrathymic T cell precursors as compared with myeloid progenitors. Over 90 genes of interest were iden- tified, and 35 of 44 tested were confirmed to be more highly expressed in T lineage precursors relative to precursors of B and/or myeloid lineage. To a remarkable extent, however, expression of these T lineage-enriched genes, including zinc finger transcription factor, helicase, and signaling adaptor genes, was also shared by stem cells (Lin؊Sca-1؉Kit؉CD27؊) and multipotent progenitors (Lin؊Sca-1؉Kit؉CD27؉), although down-regulated in other lineages. Thus, a major fraction of these early T lineage genes are a regulatory legacy from stem cells. The few genes sharply up-regulated between multipotent progenitors and Pro-T cell stages included those encoding transcription factors Bcl11b, TCF-1 (Tcf7), and HEBalt, Notch target Deltex1, Deltex3L, Fkbp5, Eva1, and Tmem131. Like GATA3 and Deltex1, Bcl11b, Fkbp5, and Eva1 were dependent on Notch/Delta signaling for induction in fetal liver precursors, but only Bcl11b and HEBalt were up-regulated between the first two stages of intrathymic T cell development (double negative 1 and double negative 2) corresponding to T lineage specification.
    [Show full text]
  • Regulation of the Expression of DAPK1 by SUMO Pathway
    biomolecules Article Regulation of the Expression of DAPK1 by SUMO Pathway 1, 1, 1, 1 1 1 1 Qingshui Wang y, Xiuli Zhang y, Ling Chen y, Shuyun Weng , Yun Xia , Yan Ye , Ke Li , Ziqiang Liao 1, Pengchen Chen 1, Khaldoon Alsamman 2 , Chen Meng 1, Craig Stevens 3, Ted R. Hupp 4 and Yao Lin 1,* 1 Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation, College of Life Sciences, Fujian Normal University, Fuzhou 350117, China; [email protected] (Q.W.); [email protected] (X.Z.); [email protected] (L.C.); [email protected] (S.W.); [email protected] (Y.X.); [email protected] (Y.Y.); [email protected] (K.L.); [email protected] (Z.L.); [email protected] (P.C.); [email protected] (C.M.) 2 Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Dammam, Dammam 31441, Saudi Arabia; [email protected] 3 School of Applied Sciences, Edinburgh Napier University, Edinburgh EH11 4BN, UK; [email protected] 4 Institute of Genetics and Molecular Medicine, Cell Signaling Unit, CRUK p53 Transduction Group, University of Edinburgh, EH4 2XR EH4 2XR, UK; [email protected] * Correspondence: [email protected]; Tel.: +86-(0)591-22860592 These authors contributed equally to this work. y Received: 15 March 2019; Accepted: 15 April 2019; Published: 17 April 2019 Abstract: Death Associated Protein Kinase 1 (DAPK1) is an important signaling kinase mediating the biological effect of multiple natural biomolecules such as IFN-γ, TNF-α, curcumin, etc. DAPK1 is degraded through both ubiquitin-proteasomal and lysosomal degradation pathways.
    [Show full text]
  • Role of Ubiquitin and SUMO in Intracellular Trafficking
    Curr. Issues Mol. Biol. (2020) 35: 99-108. Role of Ubiquitin and SUMO in Intracellular Trafcking Maria Sundvall1,2,3* 1Institute of Biomedicine, University of Turku, Turku, Finland. 2Western Cancer Centre FICAN West, Turku University Hospital, Turku, Finland. 3Department of Oncology and Radiotherapy, University of Turku, Turku, Finland. *Correspondence: [email protected] htps://doi.org/10.21775/cimb.035.099 Abstract behaviour. In addition to e.g. chemical groups, Precise location of proteins at a given time within such as phosphate groups, proteins can be modi- a cell is essential to convey specifc signals and fed by small polypeptides, such as ubiquitin and result in a relevant functional outcome. Small SUMO. Ubiquitin and SUMO share a similar ubiquitin-like modifcations, such as ubiquitin three-dimensional structure and are principally and SUMO, represent a delicate and diverse way covalently linked at lysine (K) residues of sub- to transiently regulate intracellular trafcking strate proteins by a similar conjugation pathway events of existing proteins in cells. Trafcking (Hershko et al., 1998; Hay, 2013). Unlike ubiq- of multiple proteins is controlled reversibly by uitin, SUMO is preferentially atached at SUMO ubiquitin and/or SUMO directly or indirectly via consensus sites ΨKxE in substrates Ψ = hydropho- regulation of transport machinery components. bic residue with high preference for I or V, x = any Regulation is dynamic and multilayered, involv- amino acid) under steady state conditions, but ing active crosstalk and interdependence between under stress conditions in particular more non- post-translational modifcations. However, in consensus sites are SUMOylated (Hendriks et al., most cases regulation appears very complex, and 2016).
    [Show full text]
  • Full Text (PDF)
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.29.20248986; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Insights into the molecular mechanism of anticancer drug ruxolitinib repurposable in COVID-19 therapy Manisha Mandal Department of Physiology, MGM Medical College, Kishanganj-855107, India Email: [email protected], ORCID: https://orcid.org/0000-0002-9562-5534 Shyamapada Mandal* Department of Zoology, University of Gour Banga, Malda-732103, India Email: [email protected], ORCID: https://orcid.org/0000-0002-9488-3523 *Corresponding author: Email: [email protected]; [email protected] Abstract Due to non-availability of specific therapeutics against COVID-19, repurposing of approved drugs is a reasonable option. Cytokines imbalance in COVID-19 resembles cancer; exploration of anti-inflammatory agents, might reduce COVID-19 mortality. The current study investigates the effect of ruxolitinib treatment in SARS-CoV-2 infected alveolar cells compared to the uninfected one from the GSE5147507 dataset. The protein-protein interaction network, biological process and functional enrichment of differentially expressed genes were studied using STRING App of the Cytoscape software and R programming tools. The present study indicated that ruxolitinib treatment elicited similar response equivalent to that of SARS-CoV-2 uninfected situation by inducing defense response in host against virus infection by RLR and NOD like receptor pathways. Further, the effect of ruxolitinib in SARS- CoV-2 infection was mainly caused by significant suppression of IFIH1, IRF7 and MX1 genes as well as inhibition of DDX58/IFIH1-mediated induction of interferon- I and -II signalling.
    [Show full text]
  • System-Wide Identification of Wild-Type SUMO-2 Conjugation Sites
    ARTICLE Received 16 Oct 2014 | Accepted 26 Apr 2015 | Published 15 Jun 2015 DOI: 10.1038/ncomms8289 OPEN System-wide identification of wild-type SUMO-2 conjugation sites Ivo A. Hendriks1, Rochelle C. D’Souza2, Jer-Gung Chang1, Matthias Mann2 & Alfred C.O. Vertegaal1 SUMOylation is a reversible post-translational modification (PTM) regulating all nuclear processes. Identification of SUMOylation sites by mass spectrometry (MS) has been hampered by bulky tryptic fragments, which thus far necessitated the use of mutated SUMO. Here we present a SUMO-specific protease-based methodology which circumvents this problem, dubbed Protease-Reliant Identification of SUMO Modification (PRISM). PRISM allows for detection of SUMOylated proteins as well as identification of specific sites of SUMOylation while using wild-type SUMO. The method is generic and could be widely applied to study lysine PTMs. We employ PRISM in combination with high-resolution MS to identify SUMOylation sites from HeLa cells under standard growth conditions and in response to heat shock. We identified 751 wild-type SUMOylation sites on endogenous proteins, including 200 dynamic SUMO sites in response to heat shock. Thus, we have developed a method capable of quantitatively studying wild-type mammalian SUMO at the site-specific and system-wide level. 1 Department of Molecular Cell Biology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, the Netherlands. 2 Department for Proteomics and Signal Transduction, Max Planck Institute for Biochemistry, Am Klopferspitz 18, D-82152 Martinsried, Germany. Correspondence and requests for materials should be addressed to A.C.O.V. (email: [email protected]). NATURE COMMUNICATIONS | 6:7289 | DOI: 10.1038/ncomms8289 | www.nature.com/naturecommunications 1 & 2015 Macmillan Publishers Limited.
    [Show full text]